Curis Inc (CRIS)
Curis Inc. (CRIS) is a biotechnology company focused on the development and commercialization of targeted cancer therapies. The company specializes in discovering and developing proprietary small molecule drugs that modulate the immune response and tumor growth pathways, aiming to advance innovative treatments for cancer patients.
Company News
Biotechnology company Curis reported a narrowed Q2 2025 net loss of $0.68 per share, beating analyst expectations. The company continues advancing its cancer therapy emavusertib while facing near-term funding challenges, with cash reserves expected to last only into Q1 2026.
VISTA inhibitors are an emerging class of immunotherapeutic agents with significant potential in treating cancer and autoimmune diseases. Several companies are actively pursuing VISTA inhibitors, which offer a novel mechanism of action and broad applicability, but also face challenges such as complex development landscape and competition from exi...
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price actio...
Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Shares of Curis rose premarket Friday as analysts see biotech company as potential take-out target